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ABSTRACT
Buruli ulcer (BU) is a refractory skin ulcer caused by Mycobacterium ulcerans or M. ulcerans ssp. shinshuense, a
subspecies thought to have originated in Japan or elsewhere in Asia. Although BU occurs most frequently in trop-
ical and subtropical areas such as Africa and Australia, the occurrence in Japan has gradually increased in recent
years. The World Health Organization recommends multidrug therapy consisting of a combination of oral rifampi-
cin (RFP) and i.m. streptomycin (SM) for the treatment of BU. However, surgical interventions are often required
when chemotherapy alone is ineffective. As a first step in developing a standardized regimen for BU treatment in
Japan, we analyzed detailed records of treatments and prognoses in 40 of the 44 BU cases that have been diag-
nosed in Japan. We found that a combination of RFP (450 mg/day), levofloxacin (LVFX; 500 mg/day) and clarithro-
mycin (CAM; at a dose of 800 mg/day instead of 400 mg/day) was superior to other chemotherapies performed in
Japan. This simple treatment with oral medication increases the probability of patient adherence, and may often
eliminate the need for surgery.
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INTRODUCTION
Buruli ulcer (BU) is an infectious skin disease characterized by
widespread skin ulcers and caused by Mycobacterium ulcerans
or M. ulcerans ssp. shinshuense, a subspecies that appears to
have originated in Asia.1–3 BU has been reported in over 30
countries worldwide, most frequently in West and Central
Africa, and approximately 5000 new cases are reported annu-
ally.4 A total of 44 cases of BU were sporadically identified in
Japan between 1980 and July 2013, with the incidence steadily
rising every year since 2004.1,3,5
Although a vector and mode of transmission have not been
identified for BU, it has been suggested that M. ulcerans is
acquired through contact with aquatic environments (e.g. riv-
ers, lakes, reservoirs, wetlands).3 The Global Buruli Ulcer Initia-
tive, an international coalition sponsored by the World Health
Organization (WHO), is dedicated to raising awareness of the
diagnosis, treatment, prevention and research of this neglected
tropical disease (NTD).4 The WHO has categorized BU into
three categories primarily based on the size of the skin lesion,
which is considered a crucial factor in the treatment decisions.
Category I is a single small lesion of less than 5 cm in diame-
ter; category II is a single large lesion between 5 and 15 cm in
diameter; and category III includes a single extensive lesion of
more than 15 cm in diameter.
Surgical debridement was once a standard treatment for BU
until the WHO recommended 8 weeks of oral rifampicin (RFP;
10 mg/kg per day) and i.m. streptomycin (SM; 15 mg/kg per
day) dual therapy in 2004.6 For early stage BU, characterized
by the development of a small nodule or plaque, treatment with
oral RFP and i.m. SM dual therapy for 4 weeks or more inhibits
the growth of M. ulcerans in human tissues. This inhibition of
growth is an indication that combination antimicrobial therapy
can be used as a surgical alternative in the treatment of early
stage BU.7
In French Guiana and Australia, administration of RFP and
clarithromycin (CAM; 7.5 mg/kg per day, twice a day), or RFP
and moxifloxacin (400 mg/day) for 8 weeks have been adopted
as standard treatment regimens. The latest guidelines for con-
temporary clinical practice on the management of BU in Aus-
tralia, published in 2014, recommend either of these dual
therapies for a period of 8–12 weeks instead of surgery.8 Nien-
huis et al. performed a randomized trial in two sites in Ghana
to investigate the efficacy of two combination antimicrobial
regimens (selected using contemporary WHO guidelines) for
treating early stage BU. Patients enrolled in the trial were ran-
domly assigned to one of two treatment groups: (i) 8 weeks of
RFP and SM; or (ii) 4 weeks of RFP and SM followed by
another 4 weeks of RFP and CAM. One year after treatment,
skin lesions in 96% (group 1) and 91% (group 2) of patients
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had healed without recurrence or the need for extensive surgi-
cal debridement, indicating that the combination therapies are
effective treatments for early stage BU.9 Although both regi-
mens had similar therapeutic efficacy, switching to oral CAM
from i.m. SM after the first 4-week treatment would be prefera-
ble, as it requires fewer injections. Phillip et al. conducted a
trial in which 43 BU patients received 2 weeks of RFP and SM
followed by 6 weeks of RFP and CAM. Over a 12-month fol-
low-up period, 93% of patients healed with no recurrences,
suggesting that shortening the duration of i.m. SM administra-
tion to 2 weeks would not result in a loss of therapeutic effi-
cacy.10
In contrast, Chauty et al. reported that among 208 patients
who received a 4-week therapy of RFP and SM as recom-
mended by the 6th WHO Advisory Committee on Buruli Ulcer,
83 patients (40%) needed surgery. Administration of RFP and
SM was extended an additional 8 weeks for most of the
remaining cases (122 cases; three cases dropped out). Of the
122 patients, 90 were clinically cured, but 21 were referred for
surgery (eight patients refused surgery and three dropped
out).11 Other investigators have also reported that oral antimi-
crobial therapy alone is not effective in treating BU, and surgi-
cal intervention was required in other studies.4,7,9,12
Thus, although oral antimicrobial therapy has emerged as
an attractive alternative to surgery for BU treatment, the regi-
men, administration, duration and efficacy of the optimal treat-
ment remain undefined. To date, there are no published
studies on the efficacies of BU treatments in Asian countries,
possibly because of the much lower occurrence of reported
BU cases than in endemic countries. In the present study, we
analyzed the detailed treatments and outcomes of all reported
cases of BU in Japan (1980–2013) to evaluate the efficacy of
antimicrobial therapies and explore the most effective treat-
ment for BU.
METHODS
Patients
Forty-four cases of Buruli ulcer (BU) were evaluated for this
study. The cases consisted of 17 male patients and 27 female
patients, ranging in age from 2 to 84 years (average,
41.4  25.9), who were diagnosed between 1980 and 2013.
Diagnoses of BU were confirmed based on detection of inser-
tion sequence (IS)2404, an M. ulcerans-specific repetitive ele-
ment; polymerase chain reaction and 16S rRNA gene
sequencing for further subspecies determination and charac-
terization at the Leprosy Research Center, National Institute of
Infectious Diseases, Tokyo, Japan; and clinical manifestations
and histopathological analysis. Published work searches of
MEDLINE (http://www.ncbi.nlm.nih.gov/pubmed) and the Japan
Medical Abstracts Society (http://search.jamas.or.jp) were per-
formed to locate more detailed patient information and records
of treatment methods. Furthermore, whenever possible, we
made direct contact with the attending physicians of BU
patients to obtain reliable first-hand information about treat-
ments and prognoses. Among 44 cases of BU reported in
Japan, four were excluded from this study: one case received
surgery before oral antimicrobial therapy and we were unable
to obtain clear information on prognoses or treatments for the
remaining three cases. Thus, 91% (40/44) of all BU cases diag-
nosed in Japan through 2013 were analyzed.
Evaluation of treatment effectiveness
Treatment effectiveness was analyzed using the WHO catego-
ries of BU, size of skin ulcer, medications used for antimicro-
bial therapies and need for surgery. Each oral antimicrobial
therapy was considered effective when complete epithelializa-
tion of skin lesions was achieved without performing surgical
debridement; otherwise, the therapies were deemed “ineffec-
tive”.
Data analysis
The relevance of various factors (i.e. age, sex, size of skin
lesion, WHO category and treatment) in the prognosis of BU
was analyzed using Fisher’s exact test for categorical variables
or Welch’s two t-test for continuous variables. All statistical
analyses were performed with Easy R (EZR; Saitama Medical
Center, Jichi Medical University, Saitama, Japan), a graphical
user interface for R (version 2.13.2; The R Foundation for Sta-
tistical Computing, Vienna, Austria). This software is a modified
version of R commander (version 1.8-4) with frequently used
biostatistical functions.
Ethics statement
The use of human subjects was approved by the medical
research ethics committee of the National Institute of Infectious
Diseases, Tokyo, Japan.
RESULTS
BU in Japan
Between February 1980 and July 2013, 44 cases of BU were
diagnosed in Japan with a steady increase in the number of
cases since 2010 (Fig. 1). The cases were comprised of 17
Figure 1. Reported Buruli ulcer (BU) cases in Japan by year.
A total of 44 BU cases were identified in Japan between 1980
and 2013.
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males (39%) and 27 females (61%), but the occurrence in males
is apparently increasing (Fig. 1). The cases were sporadically
distributed nationwide (Fig. 2), with a tendency towards rural
residents. A relatively concentrated occurrence of BU (10 cases)
was identified in Okayama Prefecture (Fig. 2, the highest col-
umn), and rare concurrent familial occurrences of BU have been
reported in Fukushima and Tochigi Prefectures.
In contrast to Africa where 48% of BU patients are children
under 15 years of age, children under 15 accounted for no
more than 25% of the total in Japan, while approximately half
of the patients were over 50 years of age (Fig. 3). Thus, mid-
dle-aged and older adults have been the predominantly
affected age group in Japan. Most BU cases in Japan were
diagnosed during the fall/winter, from November to January,
rather than in summer (Fig. 4).
Skin lesion sites primarily developed on exposed body
parts, including 17 cases with lesions on the upper limbs (12
cases on the forearm, four cases on the hand, and one case
on both the forearm and the hand); 21 cases with lesions on
the lower limbs (14 cases on the femur and lower leg, four
cases on the foot, two cases on both the lower leg and the
foot, and one case on both the lower limb and the face); six
cases with lesions on the head and neck area including the
face, ear, jaw and clavicle; and one case with lesions on the
truck. Although 30 cases had a single lesion, eight cases had
two, and six cases had three lesions, most of which were less
than 5 cm in diameter and the symptoms were rather mild.
Therefore, in this study, all cases including those with multiple
lesions were diagnosed preferentially based on the size of the
lesions into category I (36 cases, 82%) and category II (eight
cases, 18%). Thus, in contrast to Africa where most cases are
still diagnosed late and one-third of the cases are diagnosed
as category III,6 advanced BU cases were not found in Japan.
Among the 44 BU cases, two patients had been treated with
steroids, and two other patients had received both cyclosporin
and steroids before they were diagnosed with BU. Twenty-one
cases were free of any underlying diseases, and four patients
had colorectal cancer, Kawasaki disease, pneumoconiosis or
complete remission of malignant lymphoma. The medical
Figure 2. Regional distribution of Buruli ulcer (BU) cases in
Japan. The numbers of BU cases are indicated by cylinders on
the map in the prefecture where they were reported. The high-
est number (10 cases) was reported in Okayama Prefecture.
Figure 3. Age distribution of Buruli ulcer (BU) patients in
Japan. The numbers of BU cases in different age groups are
shown by horizontal bars.
Figure 4. Monthly distribution of Buruli ulcer (BU) diagnoses.
The number of BU cases diagnosed each month is indicated
by bars, except for one case where onset time is unclear.
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histories of the remaining 19 cases prior to BU diagnosis were
not available. No immunocompromised individual with diseases
such as diabetes or immune dysfunction was reported.
Clear records showing the therapeutic efficacy of the
adopted oral antimicrobial therapies were found for 40 cases.
Of these, antimicrobial therapy was evaluated as “effective” in
15 cases and “ineffective” in the remaining 25 cases by the cri-
teria described in the Methods. However, there was no statisti-
cal difference between these two groups when they were
evaluated based on skin lesion sites, the number of skin
lesions and the WHO category (P = 1.0, 0.9 and 0.6, respec-
tively).
Analysis of therapeutic efficacy of oral antimicrobial
therapies
Treatment and prognosis. Therapeutic efficacy was analyzed
in the 40 BU cases with clear records of detailed treatment
methods and prognoses. The WHO-recommended oral RFP
and i.m. SM dual therapy was only adopted in two cases, while
oral RFP (450 mg/day), oral levofloxacin (LVFX; 500 mg/day)
and oral CAM (800 mg/day) triple therapy (high-dose RLC) was
the most commonly used chemotherapy for treating BU in
Japan (Table 1). To better evaluate the efficacy of antimicrobial
therapies, the 40 BU cases were divided into five groups
based on their antimicrobial regimens and whether surgery
was performed (Table 1). Patients in group A received high-
dose RLC without surgery, group B received high-dose RLC
with surgery, group C received RLC in which CAM was used
at a dose of 400 mg/day (low-dose RLC) with surgery, group D
received CAM monotherapy without surgery, and group E
included patients who received all other medications such as
cephalosporin, tetracycline and other antituberculosis drugs in
various combinations in addition to surgery (Table 1). Tosuflox-
acin (TFLX; 12 mg/kg per day) was substituted for LVFX in two
children in group A and one child in group B, as TFLX, but not
LVFX, is covered by medical insurance for children in Japan.
The duration of the treatments varied from 2 to 48 weeks, by
the end of which all cases were clinically cured.
Including both high- and low-doses of CAM, RLC triple ther-
apy was adopted in 50% of cases. High-dose RLC was admin-
istrated over 8–48 weeks (average, 25  14.5), and in most
cases was administrated for 16–24 weeks, revealing longer
average treatment duration compared with a standard 8-week
antibiotic treatment.8–11 However, a significant correlation was
not found between the duration of high-dose RLC therapy and
the size of skin lesions (Fig. 5).
Table 1. Treatment classifications and outcomes
Treatments Outcome Male Female Total Group
High-dose RLC
RFP 450 mg/day + LVFX 500 mg/day + CAM 800 mg/day† Cured 7 5 12 A
Operated 2 1 3 B
Low-dose RLC
RFP 450 mg/day + LVFX 500 mg/day + CAM 400 mg/day†
or RFP 450 mg/day + LVFX 400 mg/day + CAM 400 mg/day
Cured 0 0 0 –
Operated 1 4 5 C
CAM (200 mg/day or 800 mg/day or 15 mg/kg per day) Cured 2 1 3 D
Operated 0 0 0 –
Other medications in various combination‡ Cured 0 0 0 –
Operated 5 12 17 E
Total 17 23 40
†Tosufloxacin (TFLX) was used as a substitute for levofloxacin (LVFX) in two children in group A and one child in group B. ‡Other medications included
cephalosporin; tetracycline; antituberculosis drugs; and non-simultaneous administration of rifampicin (RFP), clarithromycin (CAM) and LVFX. Oral
RFP, oral LVFX and oral CAM (RLC) therapy.
Figure 5. Correlation between duration of high-dose oral rif-
ampicin, oral levofloxacin and oral clarithromycin (RLC) therapy
and size of skin lesions. The diameter (maximum length) of the
skin lesion is on the X-axis and the duration of high-dose RLC
therapy is on the Y-axis. A significant correlation was not found
between the duration of RLC therapy and size of skin lesion
(Pearson correlation coefficient index, r = 0.225, P = 0.424).
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Efficacy of treatment based on the dose of CAM. Oral CAM is
usually used at a dose of 800 mg/day (or 15 mg/kg per day in
adults and 13–16 mg/kg per day in children). A lower dose of
400 mg/day was sometimes used in Japan. Among the 20
cases that adopted RLC triple therapy (groups A, B and C),
400 mg/day of CAM was administrated in five cases (all in
group C), including one case in which LVFX was also used at a
lower dose of 400 mg/day. However, surgery was needed for
all cases treated with low-dose RLC, because skin lesions
persisted after treatment. Relapse occurred in two cases
despite the continuance of low-dose RLC; however, the ulcers
healed after the treatment was switched to high-dose RLC.13,14
These findings indicate that a regimen of low-dose CAM may
not be suitable for the treatment of BU.
Therapeutic efficacy of high-dose RLC therapy. Because
high-dose RLC appeared to be an efficient therapeutic modal-
ity for the treatment of BU, we compared high-dose RLC (12
cases in group A and three cases in group B) to other regi-
mens (25 cases in total), including low-dose RLC (Table 2).
Among 15 patients treated with high-dose RLC, 12 cases
(80%) were cured without surgery, while surgery was avoided
only for three cases (12%) among patients who received other
medications (P < 0.0001, Fisher’s exact test). No side-effects
were reported during administration of high-dose RLC to these
cases. There was no significant difference between these two
groups in age, sex, size of skin lesion or WHO category
(Table 2), indicating that the higher cure rate should be attrib-
uted to the efficacy of high-dose RLC.
The three patients who received surgery after high-dose
RLC were all children, including two familial cases. Two of
these patients received surgery after 4 weeks or 10 days of
medications, because their parents opted to shorten the treat-
ments because they lived in a remote area and had difficulties
getting to the hospital. Another patient, a 4-year-old child, had
surgery after the skin lesion had not improved after 8 weeks of
high-dose RLC. None of the other cases that received high-
dose RLC therapy required surgery, regardless of the size of
the skin lesions. In fact, the case with the largest skin lesion
(60 mm 9 60 mm) was cured without surgery after a 6-month
treatment with high-dose RLC, proving its high therapeutic effi-
cacy (Fig. 6).
Three cases treated with medications other than high-dose
RLC were cured without surgery. These patients were treated
Table 2. Comparison of high-dose RLC and other medications
No. of cases Age (years) Sex (M/F)
Maximum ulcer
length†(mm)
WHO category no.
(%)
Cured without
surgery no. (%)I II
High-dose RLC 15 38.1  27.9 9/6 28.9  16.1 13 (86.7) 2 (13.3) 12 (80.0)
Others 25 44.2  25.6 8/17 22.7  16.2 19 (76.0) 6 (24.0) 3 (12.0)
P 0.485 0.107 0.305 0.686 2.68 9 105
Fisher’s exact test revealed a significant difference between high-dose oral rifampicin, oral levofloxacin and oral clarithromycin (RLC) therapy and
other medications only in the cure rate without surgery. Welch’s two t-test was used to consider age and size of skin lesion while Fisher’s exact test
was used for cure rate, sex and World Health Organization (WHO) category. †Ulcer size (maximum ulcer length) was determined in 30 out of 40 cases.
(a) (b) (c)
Figure 6. A skin ulcer cured by high-dose oral rifampicin, oral levofloxacin and oral clarithromycin (RLC) therapy without surgery.
(a) A large (60 mm 9 60 mm) skin ulcer before treatment. (b) The same skin ulcer following a 3-week regimen of high-dose RLC
therapy. The ulcer was still deep enough for an examination probe to penetrate. (c) The same skin ulcer, examined at the end of
24 weeks of high-dose RLC therapy, was fully epithelialized. (Photos were provided by Associate Professor Yoshihiro Umebayashi,
Department of Dermatology and Plastic Surgery, Akita University Graduate School of Medicine.)
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with CAM only (group D) for 12 weeks at a dose of 800 mg/
day, 8 weeks at a dose of 200 mg/day and 8 weeks at a dose
of 15 mg/kg per day (3-year-old girl, ~210 mg/day). They were
diagnosed at an early stage with relatively small skin lesions
(4 mm 9 5 mm, 15 mm 9 18 mm and 20 mm 9 20 mm,
respectively), which may explain why they could be cured by
CAM alone. When the same RLC drugs were administrated
separately, but not simultaneously, surgery was required (three
cases in group E), suggesting that simultaneous administration
of these three drugs may be necessary to create a synergistic
effect and subsequent high therapeutic efficacy of RLC triple
therapy.
DISCUSSION
Buruli ulcer has been designated an NTD, and is most frequently
reported in tropical and subtropical areas such as Africa and
Australia. Its occurrence has been steadily rising in Japan in
recent years, which is more likely due to an increased awareness
of this rare disease in Japan by clinicians rather than an actual
rise in the endemicity of the disease itself. Early diagnosis and
treatment are essential for good prognosis. Surgical debride-
ment was once the standard treatment for BU until 2004, when
the WHO issued guidance recommending an 8-week course of
oral RFP and i.m. SM dual therapy before considering surgery.6
However, it is evident that treatment with oral agents is prefera-
ble to i.m. injections that require daily access to a health facility
and present a potential risk for nosocomial and other infections.
The need for a standard approach to BU treatment led us to
analyze all reports of BU cases in Japan identified with a defin-
itive genetic diagnosis by the Leprosy Research Center,
National Institute of Infectious Diseases, Tokyo, Japan. The
data showed that multidrug antimicrobial therapy using RFP,
LVFX and CAM (at a dose of 800 mg/day) is a highly effica-
cious alternative to surgery in Japan, while RLC triple therapy
with a lower dose of CAM had limited effect.
As a therapeutic strategy to efficiently kill mycobacteria and
prevent the emergence of drug-resistant strains, the use of pow-
erful first-line bactericidal agents (such as RFP) in combination
with second-line drugs (such as LVFX and CAM) often exerts a
synergistic effect, and is widely applied in the treatment for
mycobacterial infections. Thus, a multidrug regimen containing
RFP, isoniazid (INH), ethambutol or SM, and pyrazinamide is
extensively used to treat tuberculosis.15 Likewise, RFP, dapsone
(diamino-diphenyl sulfone) and clofazimine combination therapy
is usually recommended for the treatment of leprosy.16
Rifampicin, SM, CAM and LVFX are among the drugs that
have good in vitro activity against M. ulcerans and M. ulcerans
ssp. shinshuense as indicated by their low minimum inhibitory
concentrations (MIC).5 RFP is usually recommended as the first-
line oral agent for treating BU, while the recommended second
agent varies depending on different guidelines.6,8 While the
WHO recommends i.m. injection of SM in combination with RFP
as the standard antibiotic treatment for BU,1,6 Australia recom-
mends CAM as an oral companion drug to RFP to achieve
comparable treatment effectiveness with better patient accep-
tance.1,8 Although a recurrence of skin lesions has been
occasionally reported after RFP and CAM dual therapy,17 most
available evidence supports the use of CAM at a dose of
800 mg/day, as recommended in the guidelines for BU treat-
ment in Australia, as a preferred second oral drug in a multidrug
regimen.8
Levofloxacin has often been combined with RFP and CAM
for BU treatment in Japan. LVFX is a broad-spectrum fluoroqu-
inolone antibiotic that has excellent tissue penetration. Peak
concentration of LVFX, which is higher in skin than in serum,
can be reached less than 4 h after p.o. administration. LVFX
also shows good activity against M. ulcerans and M. ulcerans
ssp. shinshuense in in vitro drug susceptibility tests.18
Other factors that favor the use of LVFX include low levels of
cross-resistance or antagonistic effects with other antitubercu-
losis drugs when it is used in multidrug therapy.18,19
Clarithromycin, a macrolide antibiotic, is widely used in mul-
tidrug therapies for the treatment of Mycobacterium avium
complex (MAC) pulmonary diseases. An in vitro study supports
previous observations that CAM is effective against M. ulcer-
ans, with MIC ranging from less than 0.125 to 2.0 lg/mL.20
Moreover, CAM typically accumulates in immune cells at the
site of infection. Thus, it may exert an intracellular antimicrobial
effect in these cells even when its serum concentration is lower
than the MIC.21 In this regard, Hasegawa et al. have reported
that 800 mg/day, but not 400 mg/day, is an effective dose of
CAM for treating MAC pulmonary disease.22
Complex pharmacokinetic interactions between CAM and
RFP have been reported, which may affect the efficacy of a ther-
apy containing these two drugs.21 CAM inhibits P-glycoprotein
(Pgp), a membrane protein that pumps its specific substrates
(e.g. RFP) out of cells,23 which may explain the higher plasma
concentration of RFP in patients receiving CAM compared with
those receiving SM in dual therapies.21 Conversely, RFP induces
production of cytochrome P450 (CYP) 3A4, an enzyme involved
in the metabolism of CAM,23,24 which would hasten the elimina-
tion of CAM from the body when used together. CAM serum lev-
els decreased to 12.5% when used with RFP,25 which may
explain the need for a higher dose of CAM (800 mg/day instead
of 400 mg/day) in combination therapy.26
Some patients received steroids and/or cyclosporin before
low-dose RLC. Therefore, there is a possibility that immunosup-
pression induced by these medications contributed to the inef-
fectiveness of low-dose RLC therapy in these cases.
Nevertheless, Onoe et al.14 reported that treatment with RFP,
LVF and CAM (the equivalent of the high-dose RLC in this study)
was effective for a recurrent skin ulcer in a patient with BU who
received steroids before surgery. Our findings show that high-
dose RLC is highly effective regardless of the size of the lesions.
However, continued administration of high-dose RLC therapy
until complete epithelialization of the skin lesions often requires
longer treatment. The healing of skin lesions can continue for up
to 12 months after completion of a standard 8-week antibiotic
treatment.8 Therefore, more studies are needed to determine the
appropriate treatment duration of high-dose RLC therapy to
avoid overtreatment. All forms of BU are now believed to
respond well to antibiotic treatment,6 although advanced cases
(e.g. cases with extensive and/or deep ulcers, or cases with
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osteomyelitis) may require longer treatment periods.27,28 Surgery
remains an alternative treatment, especially when diagnosis has
been delayed and the patient displays large ulcers. Surgery also
applies when the patient experiences severe side-effects of che-
motherapy (e.g. shock, jaundice, severe dizziness, hearing loss
or renal impairment) or antibiotic treatment is contraindicated
due to other conditions such as pregnancy.
Clinical and epidemiological features of BU (such as age dis-
tribution, sex distribution, distribution of lesion categories and
seasonal variation of occurrence) in Japan differ considerably
from those in Africa and Australia. The small ratio of child
patients is probably due to fewer opportunities for Japanese
children to encounter aquatic environments such as lakes or
rivers, compared with children in African countries. The absence
of advanced cases may be attributable to early diagnosis and
treatment in Japan. The seasonal variation of BU occurrence in
Japan could be explained by a model, in which patients are
infected byM. ulcerans in summer when they have more contact
with aquatic environments, but they do not begin to develop
symptoms and visit health facilities until after the suspected
incubation of several months. Unlike African countries, Japan
has four distinct seasons, and water environments differ signifi-
cantly through the year. Most chances for contact with environ-
mental water are limited to the summer, when the activity of
most bacteria and insects is also much greater. However, the
reservoir(s), vector(s) and transmission mode of BU in Japan
remain unclear.
All bacteria isolated from Japanese BU cases have been
M. ulcerans ssp. shinshuense, which has essentially the same
bacteriological features as M. ulcerans.1,3 Thus, high-dose RLC
therapy that is effective for treating BU cases in Japan likely has
a similar efficacy in endemic countries. In summary, high-dose
RLC therapy appears to have certain advantages and a high
level of efficacy for the treatment of BU. Further worldwide
analysis with more BU cases will be necessary to establish a
standard RLC treatment that circumvents surgery and/or SM
injection.
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